D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

To manage this workload, team members used custom-built generative artificial intelligence tools to help them plan the ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Roughly a year ago Meta and IBM launched the AI Alliance, founded with 56 other organizations to advocate for an open AI ...

FY2025 results show strong revenue growth, with cloud services up 10% y/y and total revenue up 6% y/y to $14.1 bn. Read more ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Operator: Good day, and welcome to the Eve Holding, Inc. Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oracle ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

PT: Hours after GPT-4.5's release, OpenAI removed a line from the AI model's white paper that said "GPT-4.5 is not a frontier ...